Predicting nerve damage risk from taxane chemotherapy
Official title: Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy
Funded at University of Michigan at Ann Arbor · NIH-11285481 · Data updated 2026-11-12
This project builds a tool to predict which patients getting taxane chemotherapy are likely to develop peripheral neuropathy.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $484,606 |
| NIH project number | 5R37CA277043-04 |
| Project ID | NIH-11285481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people receiving taxane-based chemotherapy (commonly used for breast and other cancers) who can provide blood samples and clinical information.
✕Less likely to help
People who are not treated with taxane drugs or whose neuropathy arises from other causes are unlikely to benefit directly from this work.
What this research studies
If I'm getting taxane chemotherapy, researchers will use blood samples and detailed symptom data from a large group of patients to look for biological signs linked to nerve damage. They will combine clinical and lifestyle information with nutrient and lipid levels (for example vitamin D, histidine, sphingomyelin) and genetic variants to create an integrated risk model. The team will validate the model using biospecimens and TIPN data collected in a large NCI-sponsored trial (SWOG S1714, ~1,336 patients). The hope is a practical prediction tool that can help inform treatment decisions to reduce the chance of long-term nerve injury.
Why it matters
Potential benefit: If successful, this could help doctors identify patients at high risk for chemotherapy-related nerve damage so treatment can be personalized to lower that risk.
How similar studies have gone: Prior smaller studies have suggested nutrient, lipid, and genetic markers linked to taxane neuropathy, but an integrated and clinically validated prediction model has not yet been established.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Hertz, Daniel Louis — University of Michigan at Ann Arbor
- Study coordinator: Hertz, Daniel Louis
Related research
Other NIH-funded projects on the same topics.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Novel pain biomarker for neuropathy that could guide therapy
A study to develop and test a biomarker that reflects how well peripherally acting pain medicines work for people with painful peripheral neuropathy.
-
Auricular vagus nerve stimulation to help HIV-related nerve pain in older adults
A new, non-invasive brain-nerve stimulation approach is being tested to help older adults living with HIV who have nerve pain.
-
Longitudinal study of how body-sense relates to chemotherapy nerve damage
This study follows people with breast or gastrointestinal cancer and healthy controls to see if brain processing of body sensations contributes to chemotherapy-induced nerve damage.
-
Understanding how early nerve excitement during chemotherapy leads to painful nerve damage
A cancer treatment study looks at why the nerve pain some patients get after paclitaxel may develop, by studying how nerves react during the infusion.
-
A new screen for chemotherapy-related nerve problems in young children
A clinician-scientist at Yale is developing a child-friendly survey to quickly screen for nerve-related side effects from cancer treatment in kids from birth to age 5.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.